Imprint Medicine develops epigenetic reprogramming therapies that aim to modify gene expression without altering DNA sequences, targeting a range of genetic disorders. Their platform uses precision epigenetic editing to reset disease‑associated epigenetic marks, offering a potential treatment pathway for conditions that are currently untreatable with conventional gene therapy.
Funding
Funding not disclosed
Founders
Product
Problem
Current genetic therapies often rely on altering DNA sequences, which can be technically challenging, carry safety risks, and face regulatory hurdles. Many diseases are driven by dysregulated gene expression rather than mutations, limiting the effectiveness of DNA‑editing approaches.
Solution
Imprint Medicine develops a platform that reprograms epigenetic mechanisms to modulate gene expression without changing the underlying DNA. By employing precise epigenetic editing tools, the company can activate or repress specific genes and cellular pathways, creating therapeutic effects while avoiding permanent genome modifications. The platform is designed to be adaptable across multiple disease areas, enabling the development of novel treatments that target the root causes of dysregulated gene activity. Data from preclinical models are used to validate efficacy and safety before advancing candidates toward clinical development.
Target Audience
Primary customers are biopharmaceutical companies and research organizations seeking epigenetic‑based therapeutic strategies for diseases driven by abnormal gene expression.
Features
- Targeted epigenetic editing using programmable DNA‑binding domains fused to epigenetic modifiers
- Ability to up‑regulate or down‑regulate gene expression without altering nucleotide sequences
- Modular platform that can be customized for different cellular pathways and disease indications
- Integrated screening pipeline to assess functional outcomes and off‑target effects in vitro
- Preclinical validation framework supporting rapid iteration of therapeutic candidates